Commercial Kardigan targets IPO to support cardiology pipeline progression Pharmaceutical TechnologyKardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies down the clinical pipeline.CardiovascularRead full story pharminent May 27, 2026 (Last updated: May 27, 2026) Pharmaceutical Technology Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies down the clinical pipeline. Cardiovascular Read full story Post navigation Previous: FDA delays verdict on AZ breast cancer drugNext: Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss Related Stories Commercial Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrand pharminent September 14, 2026 Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026